4 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 3.
By phase and status
Follow Rina-S: new trials by email Literature Review of Rina-S trials Research Report on Rina-S
Trials (filtered) newest first · largest first
All 6 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | 602 | 2026-11-01 | 2026-10-05 |
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | 688 | 2026-08-28 | 2026-11-04 |
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Recruiting | 82 | 2026-06-26 | 2026-11-03 |
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Rina-S, Bevacizumab - Ovarian Cancer, Platinum-sensitive Ovarian Cancer | Phase 3 | Recruiting | 544 | 2026-04-03 | 2026-11-16 |
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer Rina-S, IC - Endometrial Cancer, Recurrent or Progressive Endometrial Cancer | Phase 3 | Recruiting | 660 | 2025-11-28 | 2026-11-03 |
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Active not recruiting | 584 | 2025-02-07 | 2026-11-03 |
Conditions studied
Ovarian Neoplasms (5) · Fallopian Tube Neoplasms (3) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Recurrence (1)
Sponsors
Genmab (6)
Countries
Japan (4) · United States (4) · Australia (3) · Belgium (3) · Denmark (3) · Finland (3) · France (3) · Germany (3) · Italy (3) · Norway (3) · Poland (3) · Puerto Rico (3) · Spain (3) · Austria (2) · Canada (2)
NIH funding
2025 (2)